Evidence map›Paper›PMID 42346848›Full record

ArticleMedical sciences (Basel, Switzerland)2026

Persistence of Mortality-Dominant Pancreatitis Burden Despite Declining Rates, 1990-2023: An Analysis of the Global Burden of Disease 2023 Study.

Arkadeep Dhali, Ali Shan Hafeez, Dushyant Singh Dahiya, Saikat Mandal

Abstract read
In one paragraph

Article in Medical sciences (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Arkadeep DhaliAcademic Unit of Gastroenterology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield S57AU, UK.ORCID 0000-0002-1794-2569
Ali Shan HafeezDepartment of General Medicine, CMH Multan Institute of Medical Sciences, Multan 60000, Pakistan.ORCID 0009-0000-8015-033X
Dushyant Singh DahiyaDivision of Gastroenterology, Hepatology & Motility, The University of Kansas School of Medicine, Kansas City, MI 66160, USA.ORCID 0000-0002-8544-9039
Saikat MandalNIHR Nottingham Biomedical Research Centre, University of Nottingham and Nottingham University Hospitals NHS Trust, Nottingham NG72UH, UK.ORCID 0000-0003-1250-5295

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWhether the fatal and non-fatal composition of aggregate pancreatitis burden has changed over time remains unclear. We assessed long-term changes in the fatal-to-non-fatal composition of aggregate pancreatitis burden using Global Burden of Disease (GBD) 2023 estimates.

methodsWe conducted a systematic descriptive and trend analysis using publicly available estimates from the GBD 2023 Results Tool for incidence, prevalence, deaths, years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life-years (DALYs) across 204 countries and territories from 1990 to 2023. Because GBD reports pancreatitis as an aggregate cause category, the analysis could not distinguish acute pancreatitis, recurrent acute pancreatitis, chronic pancreatitis, or acute exacerbations of chronic pancreatitis. Primary analyses used age-standardised rates per 100,000 population. Four burden-composition metrics were derived within each location-year stratum: the YLL:YLD ratio, YLD:DALY proportion, deaths-to-incidence ratio, and prevalence-to-incidence ratio. Temporal trends were modelled in R version 4.5, using segmented regression, with up to three joinpoints selected by a Bayesian information criterion.

resultsGlobally, all six age-standardised native GBD measures declined between 1990 and 2023. The age-standardised incidence rate decreased from 37.62 (95% UI 32.20-43.11) to 32.91 (28.84-37.17) per 100,000, prevalence from 93.78 (69.26-126.25) to 68.92 (52.53-90.32), deaths from 1.76 (1.49-2.16) to 1.40 (1.21-1.66), YLDs from 5.70 (2.75-9.45) to 4.34 (2.18-7.04), YLLs from 55.96 (46.50-69.72) to 43.60 (36.89-53.53), and DALYs from 61.66 (50.62-75.61) to 47.94 (40.57-58.16). However, the fatal-to-non-fatal composition changed little: the global YLL:YLD ratio was 9.82 in 1990 and 10.04 in 2023, while the YLD share of DALYs was 0.092 and 0.091, respectively. Joinpoint modelling showed fluctuation rather than a sustained shift toward disability-dominant burden: the global YLL:YLD ratio was stable until 1998, increased from 1998 to 2002 (annual percent change [APC] 1.38%, 95% CI 0.42 to 2.36), and then declined modestly thereafter (APC -0.13%, -0.20 to -0.06). Burden remained higher in males, whereas females had a greater non-fatal share of total burden (YLD:DALY in 2023: 0.134 vs. 0.073). All sociodemographic index strata remained mortality-dominant in both 1990 and 2023; low-SDI settings had the greatest fatal dominance (YLL:YLD 34.94 in 1990; 24.72 in 2023). Using a descriptive YLD:DALY ≥ 0.50 benchmark, 203 of 204 countries and territories remained below the disability-dominant threshold in both years, no country crossed from below to above this benchmark, and only Georgia moved from above to below the benchmark.

conclusionsDespite declines in global incidence, mortality, and DALY rates, the aggregate GBD pancreatitis burden remained overwhelmingly mortality-dominant from 1990 to 2023. Because GBD pancreatitis combines acute and chronic pancreatitis, this finding should be interpreted as describing the modelled aggregate pancreatitis cause category rather than proving subtype-specific mortality dominance. The intensity of fatal dominance varied by sex, SDI, region, age, and country, but a structural shift toward disability-dominant aggregate burden was not observed.

Indexed as

Global Burden of DiseasePancreatitisDisability-Adjusted Life YearsHumansIncidencePrevalenceQuality-Adjusted Life YearsGlobal Burden of Diseasemorbiditymortalitypancreatitis

Identifiers

PMID42346848
PMCPMC13302943

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.